Fig. 3: Overall survival and recurrence-free survival by vaccine regimen and sex. | Nature Communications

Fig. 3: Overall survival and recurrence-free survival by vaccine regimen and sex.

From: Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial

Fig. 3

A OS for vaccine regimen and sex (p = 0.185 overall): for males/6MHP vs males/tet, HR 0.59 [95% CI 0.33–1.05]; vs female/tet, HR 0.50 [95% CI 0.25–1.01]; vs. females/6MHP, HR 0.61 [0.29–1.26], B RFS for vaccine regimen and sex (p = 0.075 overall): for males/6MHP vs males/tet, HR 0.58 [95% CI 0.35–0.97]; vs female/tet, HR 0.61 [95% CI 0.34–1.12]; vs. females/6MHP, HR 0.47 [0.25–0.89], C Landmark analysis for RFS at 1 year for males (n = 77) by vaccine regimen (HR 0.35, p = 0.02). P values are from two-tailed logrank tests. Adjustments were not made for multiple comparisons. Source data are provided as a Source Data file.

Back to article page